智通财经网·2025-05-21 06:26Core Insights - Roche's TALENTACE study achieved its primary endpoint, demonstrating significant improvement in TACE-PFS for patients with unresectable HCC who had not received prior systemic therapy [1] - The study innovatively combined immune checkpoint inhibitor atezolizumab with anti-angiogenic therapy bevacizumab and on-demand TACE, showing potential for a new treatment paradigm in HCC [1] Group 1 - The TALENTACE study showed statistically and clinically significant improvement in TACE-PFS, with the overall survival data still immature at the time of the interim analysis [1] - The study's design included TACE-PFS as the primary endpoint, providing high-level evidence for the combined treatment approach in HCC patients with intermediate to high tumor burden [1] - Safety profiles of atezolizumab and bevacizumab were consistent with previous data and underlying conditions [1] Group 2 - Roche's Vice President of Medical Affairs in China expressed excitement over the TALENTACE study results and emphasized the company's commitment to addressing local clinical needs in liver cancer treatment [2] - The company aims to enhance global research collaboration and accelerate the accessibility of innovative therapies, contributing to China's cancer prevention and control goals for 2030 [2]